Company intelligence / Profile preview

VGXI

Ownership: Private
Development stage: Commercial

Overview

VGXI has over two decades of experience delivering high-quality plasmid DNA products under cGMP conditions. It supports early research through clinical trials and commercial supply with injectable-grade plasmids critical for advanced therapeutic modalities such as gene therapy, cell therapy, mRNA therapeutics, and DNA vaccines. The company recently completed successful FDA inspections enabling client BLA approvals.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Plasmid DNAGene therapiesCell therapies including ex vivo gene-modified cells like CAR T-cell therapiesmRNA-based therapeuticsDNA vaccines
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on VGXI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGXI.

Explore the full profile